SEARCH:   Advanced

Blood, 1 April 2007, Vol. 109, No. 7, pp. 2791-2793. Prepublished online as a Blood First Edition Paper on November 21, 2006; DOI 10.1182/blood-2006-04-019836. This Article Full Text (PDF) All Versions of this Article: blood-2006-04-019836v1 109/7/2791    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Carpenter, P. A. Articles by Radich, J. P. Search for Related Content PubMed PubMed Citation Articles by Carpenter, P. A. Articles by Radich, J. P. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted April 26, 2006 Accepted November 13, 2006 Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia Paul A. Carpenter*, David S. Snyder, Mary E.D. Flowers, Jean E. Sanders, Theodore A. Gooley, Paul J. Martin, Frederick R. Appelbaum, and Jerald P. Radich Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA City of Hope National Medical Center, Duarte, CA Depts of Pediatrics & Medicine, University of Washington, Seattle, WA * Corresponding author; email: pcarpent{at}fhcrc.org. Relapse occurs frequently after allogeneic hematopoietic cell transplantation (HCT) for treatment of high-risk Philadelphia chromosome-positive (Ph+) leukemia. Administration of imatinib early after HCT might provide an effective approach for preventing recurrent Ph+-leukemia, but the feasibility of this approach has not been systematically tested. Twenty-two patients, 15 with Ph+-acute lymphoblastic leukemia and 7 with high-risk chronic myelogenous leukemia, were enrolled in a prospective study and given imatinib from the time of engraftment until 365 days after HCT. Before day 90, adults (n=19) tolerated a median average daily imatinib dose of 400 mg/day (range, 200 to 500 mg/day), and children (n=3) tolerated 265 mg/m2/day (range, 200 to 290 mg/m2). The most common adverse events related to imatinib administration were grade 1-3 nausea, emesis and serum transaminase elevations. We conclude that imatinib can be safely administered early after myeloablative allogeneic HCT at a dose-intensity comparable to that used in primary therapy. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: K. R. Schultz, W. P. Bowman, A. Aledo, W. B. Slayton, H. Sather, M. Devidas, C. Wang, S. M. Davies, P. S. Gaynon, M. Trigg, et al. Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study J. Clin. Oncol., November 1, 2009; 27(31): 5175 - 5181. [Abstract] [Full Text] [PDF] G. G. Laport, J. C. Alvarnas, J. M. Palmer, D. S. Snyder, M. L. Slovak, A. M. Cherry, R. M. Wong, R. S. Negrin, K. G. Blume, and S. J. Forman Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen Blood, August 1, 2008; 112(3): 903 - 909. [Abstract] [Full Text] [PDF] N. S. Majhail Old and New Cancers after Hematopoietic-Cell Transplantation Hematology, January 1, 2008; 2008(1): 142 - 149. [Abstract] [Full Text] [PDF] F. R. Appelbaum Indications for Hematopoietic Cell Transplantation for the Treatment of Adult Acute Leukemia ASCO Educational Book, January 1, 2008; 2008(1): 325 - 329. [Abstract] [Full Text] [PDF] E. Olavarria, S. Siddique, M. J. Griffiths, S. Avery, J. L. Byrne, K. P. Piper, A. L. Lennard, L. Pallan, J. M. Arrazi, J. B. Perz, et al. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia Blood, December 15, 2007; 110(13): 4614 - 4617. [Abstract] [Full Text] [PDF] J. M. Rowe and A. H. Goldstone How I treat acute lymphocytic leukemia in adults Blood, October 1, 2007; 110(7): 2268 - 2275. [Abstract] [Full Text] [PDF] D. A. Thomas Philadelphia Chromosome Positive Acute Lymphocytic Leukemia: A New Era of Challenges Hematology, January 1, 2007; 2007(1): 435 - 443. [Abstract] [Full Text] [PDF] H. M. Lazarus and S. Luger Which Patients with Adult Acute Lymphoblastic Leukemia Should Undergo a Hematopoietic Stem Cell Transplantation? Case-Based Discussion Hematology, January 1, 2007; 2007(1): 444 - 452. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020